Loading
SYS6010 is an experimental investigational agent whose form is not stated in the registry from CSPC Megalith Biopharmaceutical in phase 3 trials for non-small-cell lung cancer and head and neck squamous cell carcinoma, with its target not yet stated publicly.
SYS6010 is an investigational agent whose form is not stated in the registry developed by CSPC Megalith Biopharmaceutical and CSPC ZhongQi Pharmaceutical Technology. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: SYS6010will be administrated on a 14-day cycle. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT06927986 (Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）), in non-small-cell lung cancer and head and neck squamous cell carcinoma. The largest, NCT07241936, plans to enrol 444 participants with primary completion expected 2027-10-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.
1.SYS6010's antibody arm binds its target on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"SYS6010" OR ABSTRACT:"SYS6010") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SYS6010, not a curated reading list.
Shares CSPC Pharmaceutical Group, Non-small-cell lung cancer and the tag pipeline.
Shares CSPC Pharmaceutical Group, Non-small-cell lung cancer and the tag pipeline.
Shares CSPC Pharmaceutical Group, Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares CSPC Pharmaceutical Group and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.